Doppler Bio is building a reprogrammable ADAR sensor platform to detect disease-associated RNAs and produce engineered proteins to manipulate cell states without permanent genome editing.

Circle Bio is a synthetic biology company which provides high-quality and less expensive next-day plasmid sequencing service at higher throughput.

Relation deploys active-graph machine learning (ML) combined with single-cell analysis to advance therapeutic candidates for diseases with no or few good medicines.

Resilience is changing the way complex medicines are made and distributed by leveraging technology innovation to better serve scientific discovery, withstand disruptive events, and reach those in need.

Paradigm is rebuilding the clinical research ecosystem by creating a platform which enables equitable access to trials for all patients, while enhancing trial efficiency.

Branch is a preclinical stage company developing cellular barcoding technology to transform clinical decision making in oncology patients.

SameSky Health closes gaps in care, advances health equity and reduces health disparities through technology-based patient engagement solutions.

Deep Genomics uses artificial intelligence and machine learning to rapidly accelerate drug discovery and development for rare genetic and chronic diseases.

HiberCell is developing first-in-class drugs that target dormant disseminated tumor cells to help prevent the recurrence of cancer.

Spotlight Therapeutics uses novel technology for cell-specific delivery of CRISPR-Cas9 payloads, a major challenge for gene editing today.

Transition Bio is unlocking the potential of microfluidics and machine learning (ML) to discover modulators of biomolecular condensates in human disease.

Triveni Bio uses state of the art antibody discovery and optimization strategies, to selectively inhibit extracellular enzymes that, when overactive, can cause broad inflammatory response.

AppliedVR has pioneered evidence-based, immersive VRx—a new category of prescription digital therapeutics.